Gyre Reports Q2 2026 Revenue of $29.1 Million
Gyre Therapeutics reported strong sales for its commercial products ETUARY and Etorel, and affirmed 2026 revenue guidance of $100.5 to $111.0 million, though net loss widened.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day